Top

Published in:

01-01-2017 | Capsule Commentary

Capsule Commentary on Fairchild et al., Patients’ future expectations for diabetes and hypertension treatments: “Through the diet… I think this is going to go away ”

Authors: Andrew Straszewski, BA, Jeffrey L Jackson, MD MPH

Published in: Journal of General Internal Medicine | Issue 1/2017

Excerpt

This qualitative study by Fairchild et al.1 examined patient beliefs regarding diabetes and hypertension medical treatment, hope for potentially being cured or coming off medications and expectations for provider communication about the likely duration of medication use. The authors found that most patients believed they could eventually come off their diabetes medications (78 %), largely because they hoped to change their lifestyle. Others hoped advances in medical science could cure their disease. …

Fairchild PC, Nathan AG, Quinn M, Huang ES, Laiteerapong N. Patients’ future expectations for diabetes and hypertension treatments: “Through the diet… I think this is going to go away.” J Gen Intern Med. doi:10.1007/s11606-016-3871-3

Dixon JB, O’Brien PE. Health outcomes of severely obese type 2 diabetic subjects 1 year after laparoscopic adjustable gastric banding. Diabetes Care. 2002;25(2):358–363.CrossRefPubMed

Maruthur NM, Yong M, Delahanty LM, Nelson JA, Aroda V, White NH, Marrero D, Brancati FL, Clark JM. Early response to preventive strategies in the diabetes prevention program. J Gen Intern Med. 2013;28(12):1629–36.CrossRefPubMedPubMedCentral

Jackson JL. Communication about symptoms in primary care: Impact on patient outcomes. J Altern Complement Med. 2005;11(Suppl 1):s51–6.PubMed

Powers MA, Bardsley J, Cypress M, Duker P, Funnell MM, Fischl AH, Maryniuk MD, Siminerio L, Vivian E. Diabetes self-management education and support in type 2 diabetes: A joint position dtatement of the American Diabetes Association, the American Association of Diabetes Educators, and the Academy of Nutrition and Dietetics. Clin Diabetes. 2016;34(2):70–80.

Title: Capsule Commentary on Fairchild et al., Patients’ future expectations for diabetes and hypertension treatments: “Through the diet… I think this is going to go away ”
Authors: Andrew Straszewski, BA
Jeffrey L Jackson, MD MPH
Publication date: 01-01-2017
Publisher: Springer US
Published in: Journal of General Internal Medicine / Issue 1/2017
Print ISSN: 0884-8734
Electronic ISSN: 1525-1497
DOI: https://doi.org/10.1007/s11606-016-3902-0

ACC 2024 Congress Coverage

Heart Failure Video

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Capsule Commentary on Fairchild et al., Patients’ future expectations for diabetes and hypertension treatments: “Through the diet… I think this is going to go away ”

Excerpt

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 1/2017

A Cross-Sectional Online Survey of HIV Pre-Exposure Prophylaxis Adoption Among Primary Care Physicians

Nursing Skill Mix, Nurse Staffing Level, and Physical Restraint Use in US Hospitals: a Longitudinal Study

The Impact of Disability and Social Determinants of Health on Condition-Specific Readmissions beyond Medicare Risk Adjustments: A Cohort Study

Association Between Initial Opioid Prescribing Patterns and Subsequent Long-Term Use Among Opioid-Naïve Patients: A Statewide Retrospective Cohort Study

Capsule Commentary on Meddings et al., The Impact of Disability and Social Determinants of Health on Condition-Specific Readmissions Beyond Medicare Risk-Adjustors: A Cohort Study

Vital Signs Are Still Vital: Instability on Discharge and the Risk of Post-Discharge Adverse Outcomes

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page